Cutaneous squamous cell carcinoma study yields encouraging results

A novel treatment option could improve response in patients with cutaneous squamous cell carcinoma.

In a systematic review and meta-analysis published in the Journal of Investigative Dermatology, investigators used the data from 19 studies involving more than 1,300 patients with advanced cutaneous squamous cell carcinoma to examine the efficacy of the anti-PD-1 monoclonal antibody drug cemiplimab.

The investigators found that cemiplimab demonstrated positive complete and partial response, overall disease control, overall survival and disease-free survival rates. However, the patients experienced adverse effects such as fatigue, dermatitis, anemia, thyroiditis and pneumonitis.

The findings suggested that cemiplimab may help patients achieve tumor stabilization or shrinkage. The investigators concluded that the drug represented the potential for significant clinical benefit and a manageable safety profile. Nonetheless, further studies are needed to identify strategies to optimize this novel treatment option.

Read more: Journal of Investigative Dermatology

The article presented here is intended to inform you about the broader media perspective on dentistry, regardless of its alignment with the ADA's stance. It is important to note that publication of an article does not imply the ADA's endorsement, agreement, or promotion of its content.